Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) EBIT Margin (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed EBIT Margin for 4 consecutive years, with 10.29% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 19001.0% to 10.29% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 91.36% through Dec 2025, up 41082.0% year-over-year, with the annual reading at 91.36% for FY2025, 41082.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 10.29% at Phathom Pharmaceuticals, up from 30.85% in the prior quarter.
  • The five-year high for EBIT Margin was 1373.9% in Q1 2022, with the low at 10245.6% in Q4 2023.
  • Average EBIT Margin over 4 years is 995.67%, with a median of 151.69% recorded in 2025.
  • The sharpest move saw EBIT Margin plummeted -1073135bps in 2023, then soared 1004530bps in 2024.
  • Over 4 years, EBIT Margin stood at 485.75% in 2022, then tumbled by -2209bps to 10245.6% in 2023, then skyrocketed by 98bps to 200.3% in 2024, then soared by 95bps to 10.29% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 10.29%, 30.85%, and 151.69% for Q4 2025, Q3 2025, and Q2 2025 respectively.